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ABSTRACT 
 
Skeletal muscle is composed of two muscle fiber-types: Slow Oxidative (Type 1) and 
Fast Glycolytic (Type 2). As each muscle’s functionality is dependent upon its fiber-type 
ratio; disruption of muscle fiber-type differentiation directly disrupts muscle physiology. 
Since fiber-type  and overall muscle physiology are partially dependent upon innervation 
of a muscle fiber by a motor neuron, many muscular dystrophies and atrophies are 
associated with abnormalities of the neuromuscular junction (NMJ). Here, we 
characterize novel glutamate receptors at the NMJ, focusing primarily on the obligate N-
methyl-D-aspartate (NMDA) receptor subunit, NR1. First, we determine the timing of 
localization to the junction and begin to identify which NR1 isoforms are expressed in 
muscle. Then, we analyze electrophysiology experiments to detect changes in skeletal 
muscle membrane potential after treatment with glutamate receptor agonists/antagonists. 
Finally, we use Cre-loxP technology to create muscle-specific knockout mice for NR1. 
From these studies, we determine that NR1 localizes to the NMJ between 1 day and 1 
week of age in mice. We further conclude that glutamate receptors at the NMJ are 
functional, based upon changes in quantal content and mini end-plate potential (mEPP) 
frequency after antagonist treatment. Our preliminary data suggests the presence of at 
least two alternatively spliced NR1 isoforms in muscle; however we were unable to 
definitively identify the sequences of these isoforms. Overall, these results challenge the 
conventional dogma of a “simple synapse” mechanism of neuromuscular transmission, 
providing the possibility of alternative methods of treatment and therapeutics for 
muscular dystrophies and other neuromuscular disorders. 
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I 
 
Introduction  
 
Significance  
 
 Duchenne muscular dystrophy (DMD) is a recessive X-linked disorder which 
affects 1 in 3000 male births. Affected individuals experience severe skeletal muscle 
weakness and eventually a complete loss of muscle control until succumbing to 
respiratory or cardiac failure. Prognosis is variable, but average survival range is between 
14.4 and 20.5 years of age [15]. Modern treatment options such as antibiotics and assisted 
ventilation have greatly improved life expectancy [16], but have not significantly 
increased the median survival age [30]. 
The DMD gene has been cloned and encodes for dystrophin [11, 17, 19, 26, 75], a 
427 kDa structural protein which functions to (1) connect the basal lamina surrounding 
the sarcoplasmic skeletal muscle membrane to the cytoskeleton under the sarcolemma 
[36, 43], and (2) interact with major functional membrane proteins which control the 
flexibility of the sarcolemma during physiological processes [7, 43, 56]. Absence or 
dysfunction of dystrophin thereby creates dysfunction in the myocyte’s ability to 
maintain normal structure and function, eventually leading to muscle fiber necrosis.  
Arguably, maintenance in skeletal muscle structure would improve both outcome 
and quality of life for these patients. Although dystrophin-replacement therapeutic 
strategies continue to be researched, developments in the understanding of the 
pathogenesis of DMD with the ultimate goal of designing treatment strategies have 
focused on understanding all pathogenic aspects of skeletal muscle, including 
investigation of the neuromuscular junction.  
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Skeletal Muscle Physiology: A Brief Review 
 Skeletal muscle is comprised of elongated, multinucleated fibers (composed of 
several major proteins including actin, myosin, tropomyosin & troponins) which allow 
for elasticity and movement. These fibers are classified into two major types: “slow 
twitch” and “fast twitch.” “Slow twitch” (type 1) fibers contain high levels of 
mitochondria and therefore have a high oxidative capacity. These fibers work primarily 
by aerobic respiration to produce a lasting duration of action (endurance). “Fast twitch” 
(type 2) fibers contain fewer mitochondria and thereby require anaerobic respiration 
(glycolytic), but convey more energy over a shorter duration. The ratio of fiber-types 
within a given muscle is directly correlated with its overall function. For example, the 
soleus is a major lower-limb muscle used in plantar flexion (running, walking, etc.) and is 
comprised primarily of type 1 fibers given its function. In contrast, the extensor-
digitorum longus (EDL) of the lower-limb is involved in movement of the distal tarsals, 
used far less frequently than the soleus. It is predominantly comprised of type 2 fibers. 
Important to athletes and post-surgical recovery, the predominant fiber-type of a 
muscle can be trained. For example, the gastrocnemii of marathon runners would most 
likely have a higher ratio of type 1 to type 2 fibers, as these runners have trained for 
increased endurance. Conversely, the same muscle measured in sprinters would probably 
yield a higher ratio of type 2 to type 1 fibers, as these runners have trained for shorter, 
“bursts” of energy.  
 Fiber-type composition and post-synaptic membrane structure have been 
implicated in DMD. In a severe muscular dystrophy mouse model, Rafael et. al. showed 
that fiber-type ratios were altered to be predominantly oxidative, with an increase in type 
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1 fibers [54]. Webster et. al. demonstrated that fast-twitch (type 2) fibers are 
preferentially affected in DMD, suggesting that the DMD gene product specifically 
functions in type 2 fibers [73]. In many instances of myopathies and dystrophies, fiber-
type conversion results in loss of function in key muscles. Thus, understanding the 
factors leading to fiber-type differentiation is critical to understanding underlying 
mechanisms of neuromuscular disease. Fiber-type is, in part, determined by the direct 
innervation of each fiber: larger motor units provide a greater frequency of impulses and 
larger amounts of energy [12]. However, the molecular pathways from innervation 
leading to fiber-type have not been well characterized [49]. 
 The site where a skeletal muscle fiber is innervated by a motor neuron axon is a 
synapse known as the neuromuscular junction (NMJ). Release of the major excitatory 
neurotransmitter acetylcholine (ACh) at the NMJ allows for a multistep process called 
excitation-contraction coupling, which is responsible for muscle contraction [6]. After 
release from the axon, ACh binds to homogenous receptors (AChRs) in the heavily 
invaginated post-synaptic membrane. Along this membrane are characteristic folds 
divided by secondary clefts, both of which contain major structural proteins and peptides 
of physiological significance (See Figure 1-1) [21]. Disruption of this membrane has 
been observed in DMD patients [60], although the distribution of AChRs has been found 
as comparable to normal individuals [70]. Knocking out dystrophin and utrophin (a 
dystrophin homologue which partially compensates in its absence) revealed abnormal 
NMJ topology in mice [54].  
 The NMJ has classically been viewed as a simple “cholinergic synapse”. Recent 
discovery of glutamate receptors at the mammalian NMJ suggests the possibility of 
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alternative pathways in which the NMJ might function, or neuromuscular diseases might 
progress [38]. Based on work in vitro, Lee et al suggested that glutamate might be 
released by motorneurons in mammalian skeletal muscle and therefore might be 
responsible for skeletal muscle differentiation mechanisms [35]. At this point, it had not 
been investigated as to whether glutamate levels or localization vary in an in vivo model 
of skeletal muscle. If glutamate does function at the NMJ, it would follow that glutamate 
receptors there may be involved. It is intriguing to speculate that the role of these 
receptors might be involved in determining fiber type or skeletal muscle functionality, 
but these experiments have not yet been conducted. Identifying the functionality of these 
receptors is requisite to completely understanding the mammalian NMJ. 
Figure 1-1 
 
Figure 1-1: Electron micrograph of the NMJ. (A) Axon terminal. (B) Muscle. Arrows point to pre-
synaptic vesicles, containing neurotransmitters. EM Mimcrograph used with permission of W. Stark, St. 
Louis University, MO.   
 
Glutamate Receptors and Cell Signaling 
 There are three major types of ionotropic glutamate receptors: N-methyl-D-
aspartate (NMDA), α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) 
and kainate receptors (Figure 1-2). Ionotropic glutamate receptors, when activated, 
A 
B 
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become permeable to specific ions (e.g. Ca2+, Na+, K+) dependent upon the composition 
of the receptor [13]. The focus of this thesis is on characterization of the physiological 
functions of NMDA and AMPA receptors at the murine NMJ, with particular emphasis 
on NMDA receptors. 
 
Figure 1-2: Types of glutamate receptors. NMDA receptors include three major structural units, NR1, 
NR2A and NR2B. AMPA receptors include GluR1-4. This thesis will not focus on kainate receptors.  
 
 
NMDA receptors are composed of several components, including NMDA 
receptor subunit 1 (NR1), subunit 2B (NR2B) and subunit 2A (NR2A). NR1 is the 
obligate functional subunit of NMDA receptors [67], containing a high-affinity glycine-
binding site which activates the ligand ion channel [22]. Alternative splicing of the gene 
product for NR1 can lead to at least eight different protein isoforms in the brain, each 
with different localizations and functions (see Chapter II). NR1 complexes with NR2x 
subunits which serve to reduce the potency of glutamate thereby reducing the risk of 
neuronal glutamate toxicity [1, 34]. In the hippocampal region of the brain, glutamate 
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receptors (particularly NMDA receptors) are linked to memory and learning mechanisms 
including long-term potentiation [28, 49]. If the NR1 subunit is completely knocked-out, 
mice die within ten hours of birth from respiratory failure or cleft palate [18]. Single et al 
showed that dysfunctional NR1 causes death within 1 hour of birth [66]. Incidentally, 
knockout of the NR2A subunit caused no developmental changes in mice [61], firmly 
establishing NR1 as the requisite subunit in vivo. 
NR1 localizes to the secondary folds of the NMJ, however its function here 
remains unknown. A single experiment measuring the contraction of rat diaphragms after 
electrical stimulation and treatment with ACh inhibitors has led to the hypothesis that 
NMDA receptors may function as a co-transmitter with ACh at the NMJ [32, 49]. 
However, little evidence supports this hypothesis and the functional role of glutamate 
receptors at the NMJ has not been definitively elucidated. 
 AMPA receptors are widely expressed throughout the brain and are responsible 
for the most rapid excitatory neurotransmission in the brain [10, 50]. There are currently 
four subunits known: GluR1, GluR2, GluR3 and GluR4. Unlike NMDA receptors, 
AMPA receptors do not have an obligatory subunit for functionality [37]. AMPA 
receptors may function individually, or may combine to form heteromeric functional 
receptors [27, 62, 72]. Like NMDA receptors, they have been linked to cell polarity 
balance [42], long-term potentiation [57], and calcium permeability [25, 72]. Mouse 
knockouts of GluR1 were “smaller than their litter-mates during the first postnatal weeks, 
but after weaning, their size was normal” [77]. Interestingly, a knockout of GluR2 leads 
to a phenotype similar to that found in murine model of DMD, including a hunched back, 
slow movement, and death between 7 and 20 days after birth [20]. Though the structure 
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and physiological function of these receptors have been shown in brain, it has yet to be 
determined what their structures and functions might be in skeletal muscle. 
Objectives 
 The present studies will test the overarching hypothesis that NR1, the functional 
and essential subunit of NMDA receptors, functions in the development and maintenance 
of muscle fibers. Specifically, the goals of this study are to determine: (1) the timing of 
NR1 localization post-natally; (2) the normal function of glutamate receptors in murine 
skeletal muscle; (3) the composition of NR1 transcripts in skeletal muscle; and (4) 
determining the physiological or morphological consequences of ablating NR1 in murine 
skeletal muscle tissue. These studies are crucial to understanding the complete 
physiology of the NMJ, having the potential to challenge the dogma prevalent in 
neuromuscular physiology. 
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II 
 
Characterization of Glutamate Receptor Subunits at the 
Neuromuscular Junction 
 
Introduction  
 Until recently, the NMJ had traditionally been described as a simple cholinergic 
synapse. In 2009, Mays et al. demonstrated post-synaptic localization of AMPA GluR1 
and GluR2/3 subunits, as well as NMDA NR1, NR2A and NR2B subunits to the murine 
NMJ at 5 weeks of age [38]. If glutamate receptors contribute to the development of 
muscle fibers, it would follow that localization of these receptors would correlate with 
fiber type development and differentiation. We hypothesize that NR1 will localize to the 
NMJ at a time period prior to or concurrent with fiber type differentiation. 
  We further investigate the primary structure of glutamate receptor subunits found 
in skeletal muscle. In the brain, the NR1 protein can be defined by any of eight known 
splice variants which are regulated developmentally in a cell-specific manner and 
function in learning and memory [33, 44, 46, 78]. These variants arise from alternative 
splicing of the NR1 gene, which is known to contain 22 exons with splice sites between 
exons 5, 21 and 22 (see Figure 2-1) [24, 78]. Alternative splicing incorporates three 
distinct sequences into the NR1 gene referred to as the α, β, and γ exons. The α exon is 
the 63 bp sequence known as the “N1 cassette” and can be inserted into the N-terminal 
domain of the gene. The β (111 bp) and γ (114 bp) exons are adjacent at the C-terminal 
domain and respectively termed C1 and C2 cassettes, as they determine the primary 
structure of the NR1 C-terminus. The C2 cassette codes for a “stop” codon, however if 
the C2 cassette spliced out, then an alternative (C2’) cassette coding for a stop codon is 
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found 66 bp downstream of the “pan region.” The “pan region” refers to the translated 
domain between exon 5 and exon 21, which is common between all known isoforms in 
the brain [3, 33, 46, 78]. Campusano et al. have recently described an additional 
alternative splicing site of exon 11 (located in the “pan region”) in embryonic rats, 
however this isoform has not been detected post-natally [8]. Table 2-1 characterizes the 
known transcript variants. 
 NMDA receptor functionality is dependent upon both the type of NR1 isoform 
present as well as any additional heterodimeric binding that occurs with other NR2x 
subunits [76]. The presence of the N1 cassette significantly decreases agonist affinity and 
produces faster deactivation (closing of the ion channel) [14], whereas its absence 
increases the effect of L-glutamate (increased permeability of ions through NMDA-
receptor ligand channels) [59]. In NR1-deficient mouse neurons, Bradley et al. showed 
that reintroducing an NR1 mutant with a deleted C1 cassette greatly reduces the 
efficiency of NMDA receptor–driven gene expression, without disrupting the Ca2+ 
balance [5]. Expression levels of different NR1 isoforms in various brain regions have 
also been shown to change over the course of development. In the cortex of developing 
rats, Prybylowski et al. showed that C2-containing isoforms initially localizes at 1 day 
after birth, but then is replaced by C2’-containing isoforms by 7 weeks after birth [53]. It 
therefore is likely that while one isoform is predominant in skeletal muscle at a certain 
time post-natally, it might be replaced as necessary function for the receptor is altered.  
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Table 2-1 
Alternative Exon Presence Total Size of NR1 (bp)  Name of Splice 
Variant α β γ gene product 
NR1000 -  -  -  2655 
NR1001 -  -  + 2703 
NR1010 -  + -  2766 
NR1011 -  + + 2814 
NR1100 + -  -  2718 
NR1101 + -  + 2766 
NR1110 + + -  2829 
NR1111 + + + 2877 
 
Table 2-1. NR1 gene splice variant description. Subscripts: “0” corresponds with “-”, meaning the 
alternative exon is not included in the transcription; “1” corresponds with “+”, indicating the exon is 
included in the transcription for α, β, γ, respectively. The α exon corresponds with the N1 cassette (66 bp); 
the β exon is the C1 cassette (111 bp); the γ exon refers to a C-terminus cassette C2 (114 bp), which splices 
in to prevent translation of the terminal sequence C2’ (66 bp).   
Table adapted from Zukin et al. [78] 
 
 As NR1 and other glutamate receptors were recently discovered at the NMJ, it is 
not known whether these receptors are of the same amino acid sequence as those 
expressed in brain, or if other exons are alternatively spliced to create novel protein 
isoforms. Based upon known splicing of NR1 in the brain and data gathered from the 
localization experiments, we hypothesized that there are multiple splice variants of NR1 
expressed at the skeletal muscle NMJ.  
 We therefore designed experiments to determine when NR1 and other glutamate 
receptor subunits localized to the NMJ after birth; to determine if NR1 localizing to the 
NMJ correlated chronologically with fiber type development and differentiation; and to 
determine if the receptor subunit protein isoform(s) expressed in muscle was similar or 
identical to those expressed in brain. We utilized immunofluorescence to determine NR1 
localization in skeletal muscle, immunoblotting for confirmation, and fiber-type analysis 
to determine chronologic correlation. We then used PCR amplification of reverse-
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transcriptase (RT-PCR) of skeletal muscle mRNA with primers designed against several 
glutamate receptor subunits, allowing for expressed DNA (cDNA) to be sequenced for 
comparison against expressed receptor proteins in brain.  
Methods 
 
Immunofluorescence 
 8 µm sections of unfixed frozen quadriceps from C57 Bl/10 mice aged 1 day, 1 
week and 1 year, were blocked with 1% gelatin in potassium buffered saline (KPBS) for 
15 min at room temperature and rinsed for 5 min in KPBS. Sections were then incubated 
for 2 hours with polyclonal rabbit anti-NR1 antibody (Chemicon, 1:50 dilution) diluted in 
KPBS with 0.2% gelatin (KPBSG) and 1% normal goat serum. Slides were then rinsed 3 
x 5 min in KPBSG. After rinsing in KPBSG, the secondary antibody, CY3 α-rabbit 1:200 
dilution) in a mixture of KPBSG and Alexa 488-conjugated α-bungarotoxin (1:1000) 
with 1% normal goat serum was applied and incubated for 1 hour at room temperature. α-
bungarotoxin binds to endogenous nicotinic AChRs and thereby labels the NMJ. Slides 
were mounted and coverslipped with Vectashield® and the DNA-binding dye, DAPI. 
Tissues incubated with only secondary antibody was utilized as a negative-control. 
Images were taken through a Nikon Eclipse 800 epifluorescence microscope using a 
SPOT-RT slider digital camera and Spot® software.   
Immunoblots 
 Total skeletal muscle from 10-week-old C57 Bl/10 mice were homogenized in 
Newcastle buffer (4 M Urea, 75 mM Tris, pH 6.8, 3.8% SDS). Protein concentration was 
determined using the Biorad DC protein quantization kit by measure absorbance of 
samples on a spectrophotometer (Beckman Du-64) at 750 nm. 100 µg protein was then 
run out on 8% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gels at 80 V. 
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Proteins were then transferred from SDS-PAGE gels to nitrocellulose (Whatman 
International) at 80 V for 45, 80 or 110 min using a wet transfer apparatus (Bio-
Rad).Western blots were blocked in 5% nonfat milk in Tris–buffered saline with 0.1% 
Tween-20 (TBST) and 1% normal goat serum for 1 hour. Blots were then incubated with 
polyclonal rabbit-anti-NR1 primary antibodies diluted [Chemicon, 1:200] in TBST and 
1% normal goat serum for 2 hours. Blots were then washed 3 x 15 min in TBST and 
incubated with horse-radish peroxidase (HRP)-conjugated goat anti-rabbit secondary 
antibody (Jackson Laboratories) for 1 hour at 1:10,000 in TBST and 1% normal goat 
serum. Chemilluminescence (Amersham) was used for detection of bound primary 
antibody. Microsomes isolated from C57 Bl/10 total skeletal muscle via a previously 
described method were utilized as a positive control [48]. 
Fiber Type Analysis 
 Fiber type differentiation was assessed via β-nicotinamide adenine dinucleotide 
[reduced form] (NADH) staining.  8 µm quadriceps sections of C57 Bl/10 mice aged 1 
day, 1 week and 1 year were incubated at 37°C for 30 minutes in NADH stain (0.2 M 
Tris [pH 7.4], 1.5 mM NADH disodium salt [Sigma], 1.5 mM nitro-blue tetrazolium 
[Sigma]). Sections were then rinsed for 2 minutes each in 30% acetone, 60% acetone, 
90% acetone, 60% acetone, and 30% acetone sequentially and successively. Samples 
were mounted in Crystal Mounting Medium. Images were taken through a Nikon Eclipse 
800 epifluorescence microscope using a SPOT-RT slider digital camera and Spot® 
software.   
RNA Isolation and RT-PCR 
 C57 Bl/10 mouse diaphragm was dissected to enrich for NMJs by excising muscle 
tissue around the phrenic nerve. Total RNA was isolated from both NMJ-enriched 
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skeletal muscle and brain tissue using the TRIzol reagent (Invitrogen), according to the 
manufacturer's directions. Briefly, skeletal muscle tissue collected from hindlimbs and 
was homogenized with TRIzol reagent at 1 mL per 50-100 mg tissue. Chloroform was 
added at 0.2 mL per l mL Trizol and aqueous phase was removed from mixture. 
Isopropyl alcohol was added to precipitate RNA. The resultant RNA pellets were washed 
with 75% ethanol (aq) and resuspended in distilled water. RNA was then assessed for 
purity and quantified on a UV Spectrophotometer (Beckman Du-64) at 260/280 nm. To 
eliminate DNA and protein contamination, 5 µg RNA was treated with Proteinase K (50 
µg/mL; Invitrogen), RQ1-DNase I (1 mg/mL; Promega) and RNase OutTM (40 U/µl; 
Invitrogen) for 20 minutes, then extracted via phenol-chloroform method. Elimination of 
DNA contamination was confirmed by PCR of treated RNA. To produce cDNA, the 
SuperScriptTM III First-Strand Synthesis System for RT-PCR (Invitrogen) protocol was 
followed: 2 µg of purified RNA was mixed with 0.8 µl random hexamers (50 µM stock), 
0.2 µl Oligo-dT (50 µM stock), 1 µl dNTP mix (10 mM) and DEPC-treated water in a 
final volume of 10 µl. The mixture was heated to 65°C for 5 min, and then chilled on ice 
for 2 minutes. The first strand cDNA was synthesized in the following buffer: 2 µl 10X 
RT buffer, 4 µl MgCl2 (25 mM), 2 µl DTT (0.1 M), 1 µl RNase OutTM (40U/µl), and 1 µl 
Superscript III (200 U/µl), a reverse transcriptase at 25°C for 10 min followed by 50°C 
for 50 min, followed by 85°C for 5 min then stored at 4°C. cDNA presence and purity 
was assessed via PCR utilizing control primers capable of only producing a product from 
cDNA.  
PCR Analysis 
 Purified skeletal muscle cDNA was analyzed by PCR using primers specific for 
the receptors of interest. The NCBI Database was used to download cDNA gene 
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sequences for NR1, NR2A, NR2B, GluR1, GluR2 (both known splice variants, a and b) 
and GluR3. Primers were designed against these sequences using MacVector (Accelrys) 
for primer integrity and are described in Table 2-2 and Figure 2-1. All reactions were 
carried out for 35 cycles with specifics for each primer shown in Table 2-2. For PCRs 
with extension times less than three (3) minutes, Bullseye Long Taq Polymerase 
(MidSci) was utilized. For PCRs with extension times longer than (3) minutes, 
PfuTurbo® Polymerase (Stratagene) was utilized. Purified brain cDNA and mouse 
genomic DNA were utilized as a positive and negative control, respectively. A water-
only control was utilized as a template control. 
Sequencing 
 PCR products from the “pan region” of the NR1 gene (Figure 2-5 in Results 
section) were cut from a 1% agarose gel. To remove excess agarose, products were 
placed in a 600 µl microcentrifuge tube containing glass wool which was suspended 
above a 1.5 ml microcentrifuge tube. Tubes were centrifuged at 14,000 rpm for 20 min 
and the 600 µl microcentrifuge tube containing the glass wool was separated out from 
each 1.5 ml tube. PCR product was then purified by adding 3M Sodium Acetate (1:10) 
and 100% ethanol (2.5:1). The resulting DNA pellet was washed with 70% ethanol and 
allowed to precipitate for 72 hours, before being resuspended in 15 µl TE Buffer. 
Concentration and purity of DNA were recorded using the Nanodrop® 2000 (Fisher 
Scientific). DNA was sequenced (Genewiz, Inc., North Brunswick, NJ) using the reverse 
primer for the NR1 “pan region” (See Table 2-2). Mouse genomic DNA isolated from a 
tail biopsy of a C57 Bl/10 mouse was used as a control.  
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          Figure 2-1 
 
A. 
 
 
B. 
Primer 
Name Color Forward Reverse 
Exons 
incorporated 
N1 Red 
21 bp from 5' start codon 
(including start codon) 
 
1191 bp from 3' of "Pan region" 
 
α 
 
Pan Green 
813 bp from 5'  of  
"Pan region" 
 
333 bp from 3' of "Pan region" 
  
C2 Blue 
1491 bp from 5'  of  
"Pan region" 
 
63 bp from 3' end of coding 
sequence of γ exon 
β, γ 
 
C2' 
 
 
Black 
 
 
 
906 bp from 5' of 
"Pan region" 
 
 
894 bp towards 3' end,  
in a non-coding region; 
only codes if γ exon is absent 
β 
 
 
 
 
Figure 2-1. RT-PCR design, showing amplification strategy and primer locations in relationship to known 
alternatively spliced exons in brain. (A) Four regions were amplified and then sequenced: the N-terminus 
(N1), a “Pan” region common to all isoforms (Pan), and the C-terminus, dependent upon alternative 
splicing (C2, C2’). Brain cDNA was utilized as a positive control. (B) Chart indicating the exact starting 
and stopping of the primers along the NR1 gene. Each primer is designed to incorporate certain splice-
variant exons, except the “Pan” primer, which is designed to detect all isoforms present. 
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Results 
 
Immunofluorescence and NADH staining reveal that NR1 localizes to the NMJ 
coincident with fiber-type differentiation.  
 Immunofluorescence of mouse quadriceps aged 1 day, 1 week and 1 year revealed 
that NR1 localized to the NMJ between 1 day and 1 week after birth. Concurrent NADH 
staining of serial sections showed that fiber-type differentiation occurs within the same 
timeframe (Figure 2-2). Specificity of the NR1 antibody was tested by western blot 
analysis, which revealed a single band at ~120 kDa, consistent with literature values for 
the NR1 subunit (Figure 2-3). We additionally tested the NR1 antibody on muscle-
membrane proteins (microsomes), which are optimal for antibody binding to an NR1 
epitope within the context of cellular membranes. Microsomes also showed NR1 
antibody binding at ~120 kDa.  
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Figure 2-3 
                            
Figure 2-3: Western Blot analysis of NR1 on skeletal muscle and skeletal muscle microsomes. Bands at 
~120 kDa are consistent with NR1 isoform sizes found in brain [31, 69].  
 
 
Amplification of NR1 “pan region” cDNA reveals possible alternative splicing of NR1 
in skeletal muscle.  
 RT-PCR of isolated total skeletal muscle RNA (purified to remove genomic 
DNA) yielded skeletal muscle cDNA. To confirm that cDNA was isolated, PCR was 
performed using primers for the dystrophin gene that bind to exon sequences across large 
introns in genomic DNA (Figure 2-4). Using the purified and verified cDNA, we 
performed PCR used primers shown in Table 2-2 to amplify glutamate receptors and 
regions of the NR1 gene. Despite numerous attempts at optimizing the PCR reaction (i.e. 
adjusting annealing temperatures and extension times), 5 of the 11 the primer sets (to 
amplify NR1 (full), NR1 C-termini regions, NR2A, GluR2 (both isoforms) and GluR3) 
failed to produce reaction/PCR products from skeletal muscle and brain control cDNA. 
Primers for the NR1 N1 Cassette, NR2B and GluR1 receptors all showed positive bands 
for brain control, but did not show bands in skeletal muscle cDNA (Figure 2-5A). 
Interestingly, only one primer set, specific for the NR1 “pan region”, yielded two bands 
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in skeletal muscle (Figure 2-5B) and brain control (data not shown). A PCR product was 
also generated from the genomic DNA, even though the primers bound to different 
exons. The two bands from skeletal muscle were separated, purified and their nucleotide 
sequences determined (Figure 2-5C, Figure 2-6A, Figure 2-6B).   
Figure 2-4  
 
 
 
Figure 2-4: Results of RT-PCR from skeletal muscle and brain cDNA. Primers for dystrophin, a protein 
abundantly expressed in skeletal muscle were used to verify the presence of cDNA.  
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Figure 2-5  
A.  
 
B.             C.  
  
 
Figure 2-5: Results of PCR from skeletal muscle and brain cDNA using glutamate receptor subunit 
primers designed as shown in Table 2-2. (A) Brain cDNA (positive controls) produced bands on PCR with 
GluR1, NR2B and NR1-N1 Cassette primers. (B) NR1 “pan region” primers revealed two bands in skeletal 
muscle cDNA at approximately 700 bp and 550 bp in size. (C) Bands from the positive NR1 “pan region” 
primers were isolated, separated and purified. 
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 Sequencing revealed dual sequences for the NR1 lower band and were 
inconclusive for the upper band (Figure 2-6). The lower band was found to be composed 
of a complex mixture, with all unknown bases often showing strong peaks for two bases 
on chromatogram (Figure 2-7). When aligned with known mouse cDNA using 
MacVector®, a strong homology was displayed (see Appendix A at end).  
Figure 2-6  
(A) 
 
(B) 
 
 
Figure 2-6: Results of sequencing from Genewiz®. (A) Sequence produced from the lower band isolated 
in Figure 2-5C.  (B) Sequence produced from the upper band isolated in Figure 2-5C. “N” indicates 
unknown bases. 
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Figure 2-7 
 
Figure 2-7: Some peaks on chromatogram for the lower band show strong dual peaks, suggesting this 
might be a complex mixture of cDNA. Arrows indicate possible alternative peaks. Representative sample 
shown  (Genewiz).  
 
Discussion 
 The data presented herein suggest that NR1 localizes to the NMJ between one day 
and one week after birth, and is maintained there at 1 year of age. Of particular interest, 
NADH staining (Figure 2-2) confirms that between 1 day and 1 week is also the 
approximate timeframe when skeletal muscle fibers are differentiating. Combined, these 
results offer evidence that NR1 is present during fiber-type differentiation. It also opens 
up the possibility that NR1 contributes to fiber-type differentiation. However, as 
functional NMDA receptors require both NR1 and NR2x subunits, similar experiments to 
assess the expression of NR2A and NR2B subunits need to be conducted in order to test 
whether complete functional receptors are associated with fiber-type development. If we 
are able to show that the timing of NR1 and NR2A/B expression were concurrent, we 
could then ask the question: are they complexed together between 1 and 7 days post-
birth. Our lab has only demonstrated that NR2A and NR2B are both present at 5 weeks of 
age in the mouse NMJ [38]; the time period of 1 day to 1 week has not yet been assessed.  
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 While we cannot guarantee the antibody specificity for NR1, the western blot of 
NR1 (Figure 2-3) is in agreement with previous literature reports for NR1 protein size at 
~110-120 kDa. However, we did not run the proper controls on that particular western 
blot (Figure 2-3)—that is, no negative control or brain homogenate (positive) control 
were included for comparison. Though the protein bands appear at the proper size 
without other bands present, we cannot conclusively state based on this data alone that 
the NR1 antibody is not cross-reacting with another similar amino acid sequence.  Of 
note, finding an anti-NR1 antibody has been a cumbersome task. We tried at least four 
commercial anti-NR1 antibodies (both poly- and monoclonal) for western blot and 
immunofluorescence optimization. Shown are the best examples of these trails. 
 The second goal of this study was to identify which isoforms of NR1 were present 
in skeletal muscle. To do this, we isolated RNA from NMJ-enriched skeletal muscle and 
reverse-transcribed to generate the expressed DNA (cDNA). We then used primers 
specific for glutamate receptors and NR1 regions to amplify the regions in the purified 
cDNA and determine whether they were expressed at the NMJ. Only a single region—the 
region common to all known NR1 protein isoforms—was amplified, confirming that NR1 
is expressed in skeletal muscle. 
 There are several possible reasons why the other primers failed to amplify the 
receptors or NR1 regions that they were designed to detect. First, as with any primers, a 
fair portion of “guess work” is required to optimize conditions in which the PCR will be 
successful. Suggested annealing temps are provided when the primers are designed and 
ordered based upon their size and composition of the primers. Extension times are 
estimated at approximately 1 minute for every 1 kb sequence to be amplified. Even with 
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these general guides, many primers do not bind based upon formulae and estimations. It 
is possible that with the primers designed, additional reaction optimization would yield 
PCR products. Regrettably, there was not enough time for further testing. 
 Secondly, fewer mRNA transcripts of glutamate receptors are present in skeletal 
muscle. The bulk of muscle is major proteins that are hundreds of kiloDaltons in size: 
actin, myosin and tropomyosin. For a small protein found solely at the NMJ, 
amplification of mRNA transcripts for NR1 specificially might prove arduous given that 
RNA isolation and cDNA creation techniques would amplify to all RNA sequences 
expressed. However, ACh receptor mRNA has successfully been amplified from skeletal 
muscle [29] and presumably would be as rare of a transcript as NMDA receptor subunits 
given where it is expressed solely at the same junction in skeletal muscle. Thus, it is 
completely plausible that, with further optimization, future glutamate receptor 
identification using specific primers can be successful.  
 One concern might be that the failed primers were simply poorly designed. It is 
possible that the forward and reverse primers cross-reacted, or that the difference of 
annealing temperatures between forward and reverse primers was too great. However, for 
three primer sets (NR2B, GluR1 and the NR1-N1 Cassette), the positive control (brain) 
worked well (Figure 2-5A), eliminating this concern. The brain PCR product bands for 
each of these primers appeared at expected sizes (Table 2-2, Figure 2-5A). For these three 
sets, perhaps further amplification of the skeletal muscle samples (using PCR to re-
amplify the PCR product mixture) or amplification with a more efficient taq polymerase 
might have provided bands. When a positive band for the NR1 “pan region” was 
identified, the focus was shifted to identifying the sequence of that band. 
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 Based upon sequencing data, our hypothesis that multiple splice variants of NR1 
are present in skeletal muscle was supported. The dual bands from RT-PCR (Figure 2-
5B) are of different sizes from those shown in the genomic DNA controls, and also differ 
from the brain control (data not shown). After separation and sequencing, the lower band 
revealed dual gene sequences with strong homology to mouse NR1 (Figure 2-7). The 
upper band did not produce viable data; however its band is particularly strong on gels 
(Figure 2-5C). We conclude that the poor quality of isolating this band—possibly due to 
agarose contamination of the sample during gel purification—has left its sequence 
indeterminate for the time being. Further efforts to purify this band may yield a usable 
sequence for comparison to known NR1 gene splicing. However, before any further 
conclusions might be made regarding NR1’s function in the brain a definitive answer as 
to the sequencing homology between isolated skeletal muscle cDNA and known NR1 
sequences must be clarified.  
 The data presented here lay a foundation for challenging the dogma of the “simple 
synapse” of the NMJ; however, identification of NR1 expression in skeletal muscle is not 
sufficient. It is possible that these receptors, although present, are non-functional; to 
reach a conclusion, we must directly test functionality. 
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III 
 
Physiological Role of Glutamate Receptors in Normal Murine 
Skeletal Muscle 
 
Introduction 
 
 From an evolutionary perspective, it is unlikely that the presence of glutamate 
receptors would be maintained if they were not physiologically relevant. Certainly an 
argument can be made regarding vestigal traits and structures, but we cannot rule out the 
possibility of functional relevancy. Research in brain tissue has overwhelmingly defined 
the roles of NMDA and AMPA receptors in terms of mental conditioning, learning, 
intercellular signaling, long-term plasticity and other memory mechanisms, psychiatric 
and neurologic disorders and toxicity. In skeletal muscle, however, most of these 
functions are neither plausible nor relevant. Glutamate receptors are unlikely to be 
directly involved in skeletal muscle contraction due to ACh functioning as the key 
neurotransmitter. Therefore a new question is raised: are these receptors functional at the 
NMJ?  
  To address this question, we must consider how skeletal muscle functions in 
conjunction with the nervous system. Nerve impulses are propagated along a neuronal 
axon to the axon hillock, where depolarization of the membrane causes the axon terminal 
to become permeable to Ca2+. As Ca2+ rushes into the axon terminal, vesicles containing 
neurotransmitters fuse with the cell membrane towards the synapse, and their contents are 
released into the synaptic cleft. In skeletal muscle, the classical neurotransmitter is ACh. 
When ACh binds to its receptor along the primary folds of the NMJ, a Na+/K+ channel is 
opened, to which Na+ rushes in and K+ rushes out. The normal resting potential of -95 
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mV is maintained by high intracellular K+ and high extracellular Na+; when the ACh 
Na+/K+ channel is opened, a depolarization of the resting membrane potential occurs. The 
depolarization spreads to the sarcolemma-integrated T-tubule system, where it activates 
L-type Ca2+ channels to open and release Ca2+. Ca2+ then mediates muscle contraction via 
binding to the troponin complex and causing actin/myosin/tropomyosin movement.  
 As with any synapse, the key physiological event is depolarization of the muscle 
membrane for propagation of the electrochemical signal. As NMDA and AMPA 
receptors both control ion channels, they are excellent candidates to affect membrane 
potential. Based on known function of these receptors in brain, we hypothesize that 
treating myocytes with NMDA and AMPA receptor agonists will stimulate and enhance 
electrophysiological activity. Conversely, treating with NMDA and AMPA receptor 
antagonists will disrupt the normal function of the synapse in skeletal muscle. Initially to 
test this hypothesis, we injected agonists and antagonists directly into mice gastrocnemii, 
sacrificed them at varied timepoints, and observed for morphological and fiber-type 
changes. Unfortunately, this pilot experiment failed to produce results due to technical 
(chemical spreading) obstacles, and we quickly realized that more advanced methods 
would be in order.  
 We collaborated with Dr. Luis Polo-Parada, a muscle physiologist at the 
University of Missouri, one of very few who specialize in single-cell skeletal muscle 
electrophysiology techniques. Electrical stimulation of the muscle membrane is measured 
to determine activity of the synapse. At a normal NMJ, neurotransmitter-containing 
vesicles are released from the axon and depolarize the post-synaptic muscle membrane 
potential. When one vesicle is released, a very small depolarization occurs; this is 
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referred to as a miniature end-plate potential (mEPP). In a normal synaptic event, 
hundreds of vesicles are released synchronously, creating a “build-up” of mEPPs to form 
a full end-plate potential (EPP). The frequency of mEPPs would therefore indicate the 
firing of quanta (vesicles) during excitatory synapses. In several disease states, including 
myasthenia gravis and botulism, the amplitude and frequency of mEPPs is altered, 
resulting in a decreased end-plate synaptic potential (EPSP) change [47]. To test whether 
NMDA or AMPA receptor agonists and antagonists had an effect on electrical 
conduction of the NMJ, Dr. Polo-Parada measured the mEPP frequency and Quantal 
Content (defined as average mEPP amplitude/average EPP amplitude) after various 
regiments of glutamate receptor agonists and antagonists. Examples of mEPPs and EPPs 
are shown in Figure 3-1.  
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Figure 3-1 
A. 
 
B. 
 
 
Figure 3-1. Examples of EPPs and mEPPs as recorded on muscle. (A) An example of low electrical 
stimulation in a normal mouse. A single mEPP precedes the EPP (1 & 2 respectively). (B) An example of a 
higher stimulation (increased EPP frequency) after treatment with a glutamate antagonist. Notice how 
mEPP frequency is greater, indicating more quanta (neurotransmitter vesicles) are being released at the 
junction (3).  
 
 
 
 
 
 
1 
2 
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Methods 
 
Electrophysiology 
 Single-cell electrophysiology experiments were conducted by Dr. Luis Polo-
Parada utilizing modified protocols from Dr. Lynn Landmesser’s laboratory [51, 55]. 
Semitendinosus muscles from C57 BL/10 mice were excised along with the inserting 
nerve and perfused with oxygenated Tyrode’s solution (125 mM NaCl, 5.37 mM KCl, 24 
mM NaHCO3, 1 mM MgCl2,1.8 mM CaCl2, and 5% dextrose containing 1 µM ω-
conotoxin GIIIB) at room temperature. In each experiment, glutamate agonists or 
antagonists were added to the solution to discern changes in mEPPs and EPPs [potential]. 
The drug regiment is shown in Table 3-1. For intracellular recordings of the electrical 
responses, glass micropipettes (Sutter Instruments, Novato, CA) were pulled with a P-97 
Flaming/Brown Micropipette Puller (Sutter Instruments) and filled with 3 M KCl and 
connected to a Bridge Amplifier BA-1S (npi-Tamm, Germany); a resistance of 60-80 
MΩ was used. All recordings were displayed on an oscilloscope (Instek, Chino, CA), 
digitized in parallel, and stored and processed through a Digidata 1440A under the 
control of Axotape 10 Software (Molecular Devices Corporation). From each experiment, 
traces (e.g. Figure 3-1) were generated for analysis.  
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Table 3-1 
 
 
Table 3-1. Experiments determining physiological effects of glutamate agonists/antagonists at the NMJ. In 
each experiment, several drugs were added to a single muscle cell in the order prescribed (1st add, 2nd add, 
etc.) at 10-15 second intervals. Each experiment yielded different types of data; for example, Exp. 1.A 
determined if glutamate can act as a functional neurotransmitter if ACh receptors are blocked with α-BT. 
Glu = Glutamate, broad ionotropic glutamate receptor agonist; D-AP5 = D-2-amino-5-
phosphonopentanoate, NMDA receptor-specific antagonist; NBQX = 2,3-dihydroxy-6-nitro-7-sulfamoyl-
benzo[f]quinoxaline-2,3-dione, AMPA receptor-specific antagonist. α-BT = α-bungarotoxin, ACh receptor 
antagonist. All reagents were used at standard concentrations as used in neuronal physiology.  
 
 Except for experiments 5A and 5B in Table 3-1, I performed all analyses of traces 
generated by Dr. Polo-Parada using Clampfit 9® Software (Molecular Devices 
Corporation). Traces contained both EPPs and mEPPs (Figure 3-1), and all mEPPs and 
EPPs were measured for amplitude and recorded by the Clampfit program. Measurements 
were then recorded in an Excel® table and statistical analyses were conducted using 
Excel® (Microsoft Corporation). Average mEPPs, average EPPs, quantal content (QC), 
frequency of mEPPs and relevant statistical testing for significance (t-test, standard error) 
were all determined.  
 All experiments designed in Table 3-1 were conducted by Dr. Luis Polo-Parada. 
However, not all traces that he generated could be analyzed. The data for the files that 
were analyzed can be found in Table 3-2.  
Experiment # 1st Add. 2nd Add. 3rd Add. 4th Add. 
1.A α-BT Glu D-AP5 NBQX 
1.B α-BT D-AP5 NBQX Glu 
2.A α-BT NBQX D-AP5 Glu 
2.B D-AP5 NBQX Glu α-BT 
3.A D-AP5 NBQX α-BT Glu 
3.B D-AP5 Glu NBQX α-BT 
4.A NBQX Glu D-AP5 α-BT 
4.B NBQX D-AP5 α-BT Glu 
5.A Glu D-AP5 NBQX α-BT 
5.B Glu NBQX D-AP5 α-BT 
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Table 3-2 
 
Table 3-2. Electrophysiology measurements of normal semitendenosus muscle. Duration refers duration of the entire recorded trace. Avg. EPPs were calculated 
as (Σ EPP amplitudes)/# of EPPs. Avg. mEPPs were calculated as (Σ mEPP amplitudes)/# of mEPPs. mEPP frequency was calculated as (# of mEPPs)/duration 
of trace. Quantal Content (QC) was calculated using the formula (Avg. EPPs / Avg. mEPPs). Treatments administered are denoted for each trace; “control 
prep” refers to no treatment. Black bars in the “Treatment” column indicated separate the data from different C57 mice.  
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Results 
 The data generated from analyzing the physiology traces are listed in Table 3-1. 
Blocking NMDA receptors with DAP-5 alone yielded an increased (but not statistically 
significant) response in mEPP frequency and a decreased (but not significant) response in 
QC (red bars, Figure 3-2, Figure 3-3, Figure 3-1B). However, a nearly statistically 
significant increase in both mEPP frequency and QC were observed after treatment with 
the NMDA receptor antagonist, DAP-5, and the AMPA receptor antagonist, NBQX 
(yellow bars, Figure 3-2, Figure 3-3). 
Figure 3-2 
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Figure 3-2. Graph showing mEPP frequency from myocytes that were untreated (Control), adding an 
NMDA antagonist (DAP-5 alone) and adding two glutamate antagonists (DAP-5 followed by NBQX). 
Significance: DAP-5 — p< 0.781; DAP-5 followed by NBQX — p< 0.073.  
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Figure 3-3 
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Figure 3-3. Graph showing quantal content from myocytes that were untreated (Control), adding an 
NMDA antagonist (DAP-5 alone) and adding two glutamate antagonists (DAP-5 followed by NBQX). 
Significance: DAP-5 — p< 0.381; DAP-5 followed by NBQX — p< 0.085.  
 
 Due to the fact that sample size was n = 1 mouse for all other experiments, 
statistical analyses could not be conducted. However, it is worth noting that our data in 
Table 3-2 are consistent with previous findings that blocking ACh receptors with α-
bungarotoxin continues to arrest all action potential propagation at the NMJ (Trace 
#2008-07-15-0009, where the frequency of both mEPPs and EPPs were reduced to zero). 
It is also interesting to note that blocking AMPA receptors at the NMJ with NBQX 
(Table 3-2, Trace #2008-07-16-0004) showed an increase in the quantal content released 
at the NMJ, but did not show a dramatic change in mEPP frequency. When glutamate 
was added to the system after blocking AMPA receptors, a significant decrease in quantal 
content occurred (Table 3-2, Trace #2008-07-16-0009).  
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Discussion 
 
 Despite the sample size limitation, we were able to discern useful data from the 
electrophysiology experiments. Blocking the entire glutamate system yields a near-
statistically significant increase in both mEPP frequency and quantal content (QC). In 
other words, vesicles at the NMJ are being released much more frequently and in greater 
amounts. Perhaps the glutamate system is involved with maintaining normal vesicle 
release and disruption of this system leads to over-loading of the system. When we 
blocked NMDA receptors alone, we found no significant change in either QC or mEPP 
frequency from the controls (p values were significantly high at 0.381 and 0.781, 
respectively; Figure 3-2, Figure 3-3). Consequently, blocking AMPA receptors produced 
similar results in the single samples in which they were investigated (Table 3-2). 
However, treating the NMJ with glutamate appeared to overwhelm the system and 
dramatically decrease QC. Increasing the sample sizes for the DAP-5 and DAP-5 + 
NBQX experiments may allow our findings to reach statistical significance (p< 0.05).  
 Blocking ACh receptors at the NMJ arrested all electrical conduction in the 
muscle. We then attempted to block NMDA receptors to see if we might “rescue” 
electrical conduction, but this did not occur, suggesting that the muscle glutamate system 
is electrically-dependent upon action potential propagation to function. We had originally 
designed an experiment to test whether blocking AMPA receptors would produce the 
same effect (Table 3-1, Experiment 2A), however traces for this experiment were not 
received/analyzed. Therefore, the role of the glutamatergic system in skeletal muscle with 
respect to the cholinergic system present there is inconclusive, based upon the studies that 
we have conducted and analyzed. Further analysis of the other trace files from these 
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experiments might potentially yield answers to this question, as well as to delineate the 
specific role of NBQX and DAP-5 at the NMJ. Despite this setback, however, we also 
tried an additional method by which we would measure function of glutamate receptors—
particularly the NR1 subunit—at the NMJ, by removing the protein of interest, and 
observing phenotypical changes in mice. These experiments are described in Chapter IV.  
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IV 
 
NR1 ablation in Skeletal Muscle is not obtained via the Cre-lox 
mechanism using the HSA promoter 
 
Introduction 
 The most direct, physiologically-relevant method for testing the function of a 
protein is to knock out its corresponding gene and analyze changes in phenotype. For 
several decades researchers have completely knocked-out genes in animals—“total 
knockouts” (tKO)—and defined functionality of specific genes and their corresponding 
proteins. However, as genes are often variably expressed in different tissues, the 
knocking out of a gene in all tissues does not allow for tissue-specific testing of 
functionality. For example, if a tKO mouse does not survive long enough for further 
testing, and/or it is known that the protein is expressed in multiple tissues, it is difficult to 
connect lethality with its role in a specific tissue. Such is the case for NR1, where tKO 
mice do not feed and die within 10 hours of birth from respiratory failure [18]. Further, a 
tKO model does not necessarily allow for protein function to correlate with gene 
expression in a particular tissue, as observed phenotypes in one tissue might mask 
phenotypes observed in other tissues. 
 In the mid 1990s, a method in which genes of interest might be knocked-out in a 
tissue specific manner was discovered. This method involved using a well-characterized 
bacterial recombination system referred to as the “locus of crossover P1” (loxP)–Cre 
recombination system [68]. The loxP-Cre recombination system requires two loxP sites 
(DNA regions characterized by 8 bp asymmetric sequence flanked by two palindromic 13 
bp sequences) on the same chromosome and an enzyme called Cre recombinase (Cre) 
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(Figure 4-1A). If the loxP sites are inserted in a cis fashion (Figure 4-1B), Cre will 
specifically cleave within the 8 bp buffer sequence to eliminate a single loxP site and any 
intervening DNA [23, 45]. By flanking genes of interest in undifferentiated mammalian 
cells with loxP sites in the presence of Cre, Sauer et al. demonstrated that gene-specific 
cleavage can be induced in mammalian cells [63, 64]. The loxP sites are located in each 
cell in the organism, but by expressing Cre specifically in a tissue of interest; one can 
eliminate a loxP flanked gene (termed “floxed” gene) within that tissue alone. In 1996, 
Tsien et al. designed a flox transgenic mouse line with loxP sites flanking the NR1 gene 
[71]. When a homozygous NR1 flox mouse was mated with a mouse with Cre coupled to 
a hippocampal cell gene promoter, Tsien et al. successfully excised the NR1 gene solely 
from CA-1 pyramidal cells in brain.  
 In this thesis, we sought to determine whether ablation of a glutamate receptor in 
skeletal muscle would lead to any change in phenotype. This question inherently posed a 
second question: could NMDA receptor subunits actually be ablated specifically in 
skeletal muscle? To address these questions, we designed experiments to ablate NR1 
selectively from murine skeletal muscle. NR1 was an optimal glutamate receptor subunit 
candidate for these studies for several reasons. First, NR1 is the obligate subunit; ablating 
it would render any NMDA receptor complexes dysfunctional. Second, the mice from 
Tsien et al. (NR1 flox) are already developed and maintained by Jackson Laboratories, 
making them easily accessible for breeding, genotyping and experimentation. Finally, by 
ablating NR1, we can determine if there is any correlation between NR1 and fiber-type 
development, as previous data have shown (Chapter II—Immunofluorescence data). In 
this study, we will test the hypothesis that absence of NR1 from the NMJ will result in 
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abnormal skeletal muscle development and maintenance. To test this hypothesis, we will 
mate these NR1 floxed mice against a muscle-specific Human Skeletal Actin (HSA) Cre 
line, developed by the Melki Lab at the Université Louis Pasteur (Strasbourg, France) 
[40]. The HSA promoter is known to be skeletal muscle-specific and is expressed from 
prenatal myocyte differentiation [4]. From this mating, a conditional knockout (cKO) 
mouse will be created, in which we will confirm NR1 ablation with immunofluorescence 
and Western analysis. We will also test cKOs for muscle morphology and fiber-type 
differentiation at various ages.  
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Figure 4-1 
 
A. 
 
 
B. 
 
Figure 4-1: (A) Illustration of the loxP site. An 8 bp asymmetrical region is flanked by two palindromic 
regions. Cre recombinase cleaves in the assymetrical 8 bp region. (B) A schematic detailing Cre-loxP 
recombination. When the loxP sites are in a cis arrangement, they may be complimentarily cleaved by Cre 
recombinase (dashed line) and resealed to form two products. The circular DNA containing the gene of 
interest will be degraded naturally, and only a single loxP site remains on the chromosome.  
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Methods 
NR1 Mutant Mice and HSA Transgenic line 
 Mice with a single floxed allele for the GRIN1 gene encoding the NR1 subunit of 
the NMDA receptor used in the experiments were initially created by Tsien et al. and 
purchased from Jackson Laboratories (Bar Harbor, Maine). This allele contains loxP sites 
flanking 9 exons of the Grin1 gene.  (loxP inserts were placed between exons 10 and 11, 
and 3 kb downstream of the final exon) [71]. Human Skeletal Actin (HSA) transgenic 
mice were created by the Melki laboratory and have been repeatedly established to show 
skeletal muscle-specific expression of Cre recombinase [40]. These mice were received 
by our lab several years ago from Jackson Laboratories and have been breeding well. All 
animals are housed in a fully-equipped and staffed vivarium at The Ohio State 
University, under an IACUC approved protocol to Dr. Jill Rafael-Fortney, Department of 
Molecular and Cellular Biochemistry. Mice were housed on a standard 12 hr light/day 
cycle and were provided food (7012 Teklad LM-485 Mouse/Rat Sterilizable Diet, Harlan 
Laboratories) and water ad libitum. 
 NR1 flox (NR1) homozygous mice (NR1 flox/flox) were bred with mice carrying 
the HSA Cre transgene (Cre+). The F1 generation resulted in NR1 heterozygous mice 
(NR1 flox/wt) with and without the transgene (Cre+). Floxed heterozygotes containing 
the HSA Cre transgene (NR1 flox/wt Cre+) were mated with the homozygous (NR1 
flox/flox Cre-) F1-generation mice to produce the F2 generation which contained the NR1 
flox/flox Cre+ (NR1 cKO). NR1 cKO mice from the F2 generation were utilized 
experimentally, with unfloxed and floxed Cre- littermates being used as controls (see 
Figure 4-2 in Results Section). 
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Genotyping of Mice 
 DNA from tail biopsies was analyzed by PCR. Primers utilized to screen for 
floxed-NR1 were used as described in Tsien et al. [71]. These included a forward primer 
for the flox allele, designed to detect a neomycin resistance gene inserted along with the 
loxP sites in creation of the mice, (5′ CTT GGG TGG AGA GGC TAT TC 3′) and a 
reverse primer (5′ AGG TGA GAT GAC AGG AGA TC 3′). For the wild-type (wt) 
allele, the forward primer was (5’ GTG AGC TGC ACT TCC AGA AG 3’) and the 
reverse primer was (5’ GAC TTT CGG CAT GTG AAA TG 3’). Reactions for the flox 
and wild-type (wt) alleles were carried out on genomic DNA for 35 cycles under the 
following conditions: 94°C, 30 s; 61°C, 30 s; 72°C, 45 s. Primers utilized to screen for 
the HSA Cre trangene included forward primer (5′ AAG TGA AGC CTC GCT TCC 3′) 
and a reverse primer (5′ CCT CAT CAC TCG TTG CAT CGA 3′). Reactions were 
carried out on genomic DNA for 35 cycles under the following conditions: 94°C, 30 s; 
55°C, 30 s; 72°C, 1 min. Following PCR, reaction products were run out on 1% agarose 
gels (Tris-boric acid-based buffer) containing ethidium bromide and photographed under 
UV light. 
Histology 
 Tissues from mice sacrificed at 17 weeks were excised and embedded either 
unfixed (for epifluorescence) or fixed with formaldehyde (for confocal 
immunofluorescence; see protocol below) in a cryoprotective medium Tissue-Tek. 
Tissues were then frozen over isopentane in liquid nitrogen. Tissues were stored at -80ºC. 
Frozen sections (8 µm) of quadriceps, diaphragm and soleus were cut on a cryostat. 
Hematoxylin and eosin staining (H&E) was performed using standard procedure. 
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Immunofluorescence 
 For epifluorescence visualization, immunofluorescence for NR1 was conducted as 
previously described (see Chapter II) on 8 µm sections of unfixed frozen quadriceps with 
the primary polyclonal rabbit anti-NR1 antibody (Chemicon, 1:50 dilution) and 
secondary antibody CY3 α-rabbit (Jackson ImmunoResearch Laboratories, 1:200 
dilution). NMJs were labeled with Alexa 488-conjugated α-bungarotoxin (1:1000) and all 
samples were counterstained with DAPI. Images were taken with a Nikon Eclipse 800 
epifluorescence microscope using a SPOT-RT slider digital camera and Spot software.   
 For confocal microscopy, excised quadriceps were fixed in 1% p-formaldehyde 
(aq) for 1 hour and then stored in a sucrose solution (20% in KPBS) overnight. Tissues 
were embedded in Tissue-Tek and frozen over isopentane in liquid nitrogen. 
Immunofluorescence for NR1 was conducted as stated above on 8 µm sections. Images 
were taken with a Zeiss 510 META laser scanning microscope (Thornwood, New York) 
at 63x objective lens.  
Immunoblots 
 Protein isolation, concentration measurement and western blotting was performed 
as previously described (see Chapter II) on total skeletal muscle isolated from NR1 
conditional mice at 17 weeks of age; mdx (dystrophin knockout) and dko (utrophin and 
dystrophin knockout) at 10 weeks of age. Both an NR1 antibody specific to the C-
terminus (Chemicon, 1:500 dilution) and specific to the “pan region” (Pharmingen, 
1:250) were used. Brain taken from C57 Bl/10 mice were used as positive controls.  
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Results 
 
Generation of NR1 loxP-Cre mice. 
 
Figure 4-2 
 
Figure 4-2: Mating pedigree for NR1 cKO mice. (I) NR1 flox/flox Cre Tg- x NR1 wt/wt Cre Tg+ yielded 
NR1 flox/wt Cre Tg-/+ litters. (II) A heterozygote (NR1 flox/wt Cre Tg+) was mated with a homozygote 
(NR1 flox/flox Cre Tg-) to yield a variety of offspring (III) of which approximately 25% were the correct 
genotype of interest, NR1 flox/flox Cre Tg+. 
 
 NR1 flox/flox Cre– mice were bred with mice carrying the NR1 wt/wt Cre+. PCR 
was used to determine genotypes of offspring (Figure 4-3). The F1 generation consisted 
of NR1 heterozygous mice (NR1 flox/wt) with and without the Cre transgene (Cre+). 
Heterozygous Cre+ mice (NR1 flox/wt Cre+) were then mated to the homozygous mice 
(NR1 flox/flox Cre–) to produce the F2 generation, containing all expected genotypes in 
Mendelian ratios (10:15:21:13) for heterozygous transgenic positive (NR1 flox/wt Cre+), 
heterozygous transgenic negative (NR1 flox/wt Cre–), homozygous transgenic negative 
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(NR1 flox/flox Cre-) and NR1 cKO (NR1 flox/flox Cre+), respectively. NR1 cKO mice 
from the F2 generation were used experimentally (Figure 4-2). All phenotypes of mice 
appeared overtly normal up to 12 months of age.  
 In later experiments, NR1 cKOs were mated with each other to create “double-
transgenic” mice. Though PCR could not used to identify double-transgenics, as the 
transgene band was already strong in PCR (see Figure 4-3), we decided to analyze all 
mice histologically and later confirm genotypes if advantageous or necessary.   
Figure 4-3 
 
Figure 4-3: PCR products of mouse genotyping (representative samples) separated on 1% agarose gels 
containing ethidium bromide. Wild-type (wt) product is expected at ~70 bp, flox product at ~270 bp, and 
transgene product at ~700 bp. * On rare occasion, the neo resistance cassette (detects Cre transgene on 
PCR) can be amplified dependent upon number of copies of the cassette present. 
 
Muscle Damage is not apparent at 17 weeks of age in NR1 KO mice. 
 In humans and mice with muscular dystrophy, extensive skeletal muscle damage 
is present. Therefore, we first investigated whether NR1 cKO mice displayed a similar 
phenotype. Muscle damage is characterized by a severe atrophy or loss of muscle fibers, 
the appearance of regenerating fibers as signaled by centrally-localized nuclei and/or the 
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presence of inflammation. However, Figure 4-4 shows that no extensive muscle damage 
was observed in the NR1 cKO mice—they were histologically comparable with control 
mice. All mice had similar-sized muscle fibers, with nuclei located peripherally denoting 
non-regenerating fibers and no inflammation. These data suggested one of three 
scenarios: (1) Cre was not functioning to excise this particular loxP flanked gene; (2) Cre 
was not expressed in synaptic nuclei of the NMJ where NR1 is exclusively expressed 
(Figure 2-2); or (3) NR1 is being excised, but the mice do not show muscle-degeneration 
phenotype, unsupportive of our hypothesis.  
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Figure 4-4 
 
 
 
F 
 
Figure 4-4: H&E staining of mice quadriceps at 17 weeks of age. Genotypes represented are: NR1 
flox/flox Cre+ (A & B), NR1 flox/wt Cre+ (C), NR1 flox/flox Cre— (D) and NR1 wt/wt Cre+ (E). For 
comparison, muscle degeneration is seen in a severe muscular dystrophy mouse model [dko] (F). An 
occasional fiber with central nuclei was observed (A), but not statistically different between genotypes. All 
images at 40X magnification, except dko shown at 20X. dko slide courtesy of K. Gardner, Rafael-Fortney 
Laboratory. 
 
Localization of NR1 in cKO and control skeletal muscle. 
 Following our negative histology data, we decided to confirm deletion of NR1 
protein from skeletal muscle via immunfluorescence in NR1 cKO mice. Figure 4-5 
shows NR1-staining of skeletal muscle in mice aged 17 weeks. Staining revealed no 
remarkable distinction between NR1 cKOs and control littermates, in that NR1 staining 
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was present in all genotypes. We tested a number of antibodies commercially available 
for NR1 to try and identify one that was truly specific for NR1 and was also sensitive 
enough to detect the very small amount of NR1 in skeletal muscle (over 90% of skeletal 
muscle proteins are from the contractile apparatus). We used western blot analysis to 
examine differences in NR1 protein levels and confirm antibody specificity (Figure 4-6).   
Interestingly, two bands were observed on western analysis; one smaller and one larger 
than the molecular weight of the positive control band (murine brain). The antibody used 
(mouse monoclonal NR1 anti-rabbit from Chemicon) is specific for the C-terminus of the 
NR1 protein. Incidentally, a second antibody (mouse monoclonal NR1 anti-rabbit from 
Pharmingen), which is specific to the NR1 “pan region” (see Chapter II), yielded similar 
results (Figure 4-7). Additionally, dko, mdx and C57 muscle samples were analyzed for 
comparison (Figure 4-7). The dko and mdx are mouse models of muscular dystrophy 
(severe and mild, respectively). The C57 Bl/10 mouse is a phenotypically normal mouse. 
All samples contain the double-banding pattern except the mdx sample, which appears to 
have a single band. 
 
   
 55  
 
 
Figure 4-6: Western Blot analysis of the NR1 
protein. NR1 C-terminus monoclonal antibody 
(Chemicon, 1:500 dilution) was used to detect 
levels of NR1 protein. All samples yielded two 
bands; one at ~110 kDa and one slightly larger 
than 120 kDa. Brain was utilized as a positive 
control. (Representative samples are shown).    
. 
 
 
 
 
 
 
Figure 4-6 
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Figure 4-7 
 
 
 
 
Figure 4-7: Western Blot analysis of the NR1 
protein “pan region” on NR1 flox genotypes, 
mdx, dko, and C57 Bl/10. NR1 monoclonal 
antibody (Pharmingen, 1:250 dilution) was used 
to detect levels of NR1 protein. All samples 
(except mdx) yielded two bands; one at ~110 
kDa and one slightly greater than 120 kDa. Brain 
was utilized as a positive control. 
(Representative samples are shown).   
 After determining that NR1 was not knocked out at the NMJ, we examined the 
immunofluorescently stained sections (Figure 4-5) further via confocal microscopy. The 
aim was to determine whether NR1 was simply not being targeted at the NMJ: was NR1 
still expressed in synaptic nuclei, was it expressed by the neuron, or was our Cre working 
properly and immunofluorescence showed NR1 expression at the NMJ pre-synaptically 
but not at post-skeletal muscle membrane? Determining the localization of NR1 with 
more detail than what epifluorescence could show would answer these questions and 
redirect further investigation. Figure 4-8 illustrates that the NMJs of NR1 cKO mice and 
wild-type mice each had identical localization patterns, confirming that our Cre was 
ineffective at ablating NR1 in synaptic nuclei. 
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Figure 4-8 
A.  
             AChRs                       Synaptophysin                   merge 
 
 
B.  
 
Figure 4-8: (A) Epifluorescence of the NMJ with synaptophisin, a pre-synaptic protein, illustrating that 
pre- and post-synaptic membranes can be differentiated using immunofluorescence. Asterisk (*) indicates 
post-synaptic side of the junction. Image courtesy of Mays et al. [38]. (B) Confocal microscopy using 
Alexa 488-conjugated α-Bungarotoxin (first column) to identify ACh receptors at the primary folds of the 
NMJ and CY3-conjugated NR1 anti-rabbit (polyclonal, Chemicon, middle column) detection to mark NR1 
subunits. NR1 localizes to the NMJ in all genotypes of mice. Representative NMJs shown. (63X objective 
lens used, 3x zoom).  
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Discussion 
 In this study, we attempted to test the hypothesis that absence of NR1 from the 
murine NMJ will result in abnormal skeletal muscle maintenance and development. 
However, our efforts to knockout the NR1 gene from skeletal muscle and therefore 
eliminate the expression of a functional NMDA receptor at the NMJ were unsuccessful as 
shown by immunofluorescence and western analysis using NR1-spcific antibodies. 
Confocal microscopy revealed that NR1 subunits continued to localize to the NMJ post-
synaptic membrane in NR1 cKOs (Figure 4-8). Therefore the stated hypothesis could not 
be tested due the Cre-loxP gene excision strategy not functioning properly.  
 Although the HSA Cre mouse line was designed to be expressed in skeletal 
muscle during development and differentiation, it was designed neither to be specific for 
nor inclusive of synaptic nuclei [4]. Like ACh receptor subunits, NR1 may be expressed 
exclusively from synaptic nuclei. Utilizing a Cre coupled with a different gene promoter 
might provide a more ideal recombination system for NR1 at the NMJ. For example, 
coupling the Cre transgene to a synaptic nucleus-specific gene promoter would allow Cre 
expression exclusively to that locus. Currently, the Cre transgene has not been coupled 
with any such gene promoters, however, plausible candidate genes include ACh receptors 
[39], neuregulin receptors (erbB2 and erbB4 components) [65] S-laminin or a membrane-
associated cell adhesion molecule N-CAM [41].  
 The age of mice at sacrifice must also be considered.  In this thesis, we show data 
in which mice were aged to 17 weeks before sacrifice; however we later conducted the 
same immunofluorescence experiments in cKO mice at ages 8, 10, 12 and 52 weeks. 
These mice expressed the same phenotypes as the 17-week aged mice (data not shown). 
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The 17-week old mice were chosen to represent all data, as by that point, ample time was 
assumed for complete Cre recombinase expression and formation, and protein turnover to 
have occurred.  
 A caveat to this, however, is that we did not check Cre expression in the mice or 
confirm synaptic nuclei-specific expression of the NR1 gene, which would have required 
time-consuming and labor-intensive RNA in situ experiments. To confirm Cre gene 
expression, Tsien et al. utilized a highly-specific antibody against Cre recombinase and 
showed localization exclusively to the area of interest (CA-1 region of the hippocampus). 
We suspect that Cre was expressed in muscle fibers where NR1 is not shown to be 
expressed, thus no phenotype would be observed. To test this hypothesis, we can use an 
anti-Cre antibody to investigate localization via immunofluorescence, or can test for the 
presence of Cre recombinase via western blot analysis. It is likely that synaptic nuclei do 
not express the gene promoter (α-actin) to which Cre was coupled in our construct. We 
would therefore expect Cre to be found as localized to the body of the muscle fiber rather 
than the synapse. 
 Of particular note, our western blot analysis shows two NR1 bands using the “pan 
region” antibody and two bands using the C-terminus polyclonal antibody. The sizes of 
the bands at 110-120 kDa, are consistent with literature values reported in brain (due to 
alternative splicing, protein size varies; see Chapter II) [31, 69]. We must, however, 
acknowledge the possibility that the NR1 antibodies utilized may not be specific to the 
NR1 protein isoforms. Homologous proteins, with only a few amino acids varying from 
the epitopes which anti-NR1 antibodies detect, are certainly possible in skeletal muscle. 
But, the difference in size of NR1 isoforms shown is consistent with data previously 
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generated (see Chapter II) reinforcing the suggestion of alternative splicing in the NR1 
gene in skeletal muscle.  
 While the NR1 cKO mice did not work as predicted in these experiments, we did 
observe two bands in western blot analysis using two different NR1 antibodies. Further 
experiments could determine if Cre is expressed at the NMJ under the HSA promoter, or 
perhaps a different Cre system might be specifically knocked-out in the NR1 gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 61  
V. 
 
Discussion and Future Directions 
  
Localization of the NR1 subunit 
 The studies I present in this thesis sought to test the overarching hypothesis that 
NR1, the functional and obligatory subunit of NMDA receptors, functions in the 
development and maintenance of skeletal muscle fibers. We first used 
immunofluorescence to show that NR1 localizes between one and seven days post-birth, 
coinciding with fiber-type differentiation. Though it can not be definitively stated that 
functional NMDA receptors are formed at that junction in the same timeframe, 
demonstrating a chronologic correlation of the functionally obligatory subunit with fiber-
type differentiation supports the hypothesis that NMDA receptors are involved in fiber-
type determination. As NR1 must complex with NR2x subunits to create a functional 
receptor, the evidence presented here warrants further investigation as to the localization 
timeframe of other glutamate receptor subunits, including NR2A and NR2B. Should the 
timeframe correspond to NR1 localization, it might be beneficial to use co-
immunoprecipitation to isolate the protein complex formed to create the functional 
receptors. Identification of the components of functional NMDA receptors in muscle will 
further delineate the functional roles of the receptors and will provide insight into the 
modulation of these receptors for therapeutic purposes. In the brain, identification of the 
NMDA complex components has led to therapeutics specifically targeted to affect 
binding and activity of the channels to which they are linked [52]. 
 Whether NMDA receptor localization is disrupted in murine models of muscular 
dystrophy has not yet been published. In dystrophin/utrophin double-knockout (dko) 
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mice, slow muscle fiber-types are predominant in limb muscles where mixed fiber-types 
are typical in normal mice [2]. If irregular or disrupted localization of NMDA receptors 
in skeletal muscle could be correlated to fiber-type differentiation in dko mice, stronger 
evidence of a functional role would be present.  Data recently generated in our laboratory 
show disrupted localization of both AMPA and NMDA receptors in mdx and dko mouse 
models at 10 weeks of age [data not shown]. However, NR1 protein expression levels 
would represent a better comparison between these models, but the western blot analysis 
requisite for comparing protein levels is dependent upon finding a functional primary 
anti-NR1 antibody (Chapter II). Despite this setback, further analysis of glutamate 
receptor complexes in dko skeletal muscle might provide useful insight into the workings 
of the NMJ and warrants further investigation. 
Primary Structure of the NR1 subunit 
 As structure often directly correlates with function, investigation of the primary 
structure of NR1 found in skeletal muscle might allude to its function there. To determine 
the protein structure of NR1 expressed in skeletal muscle, we amplified NR1 mRNAs 
from skeletal muscle.  Using reverse transcriptase, we created the corresponding cDNA 
sequence, which was then compared to known splice variants found in brain, as NR1 is 
known to be alternatively spliced at no less than three exons [46, 78]. While RT-PCR was 
able to amplify two bands in skeletal muscle, the NR1 complex transcripts have not yet 
led to definite sequences. Instead, what is believed to be a complex mixture of two 
sequences was isolated from a lower band and the upper band was inconclusive. 
 If there are in fact multiple sequences being expressed, inserting each sequence 
into separate plasmids might allow for the sequences to be identified. Bacterial plasmids 
   
 63  
digested with restriction enzymes using a ligation reaction. Each plasmid would 
theoretically only incorporate one of the sequences. Plasmids could then be transformed 
into competent E. coli cells, plated and the correct plasmid incorporation could be 
confirmed via PCR. Transformed E. coli can be cultured to create clonal colonies, from 
which plasmid DNA can be isolated for sequencing.  
 Another way we could approach determination of primary amino acid structure 
would be to directly test the protein variants. Using an SDS-PAGE gel, we could isolate 
proteins via molecular weight (and, if necessary, by charge). The proteins of interest 
could be identified by staining, excised from the gel; then digested with a protease (e.g. 
chymotrypsin). The resultant protein fragment mixture could be analyzed by mass 
spectroscopy and computationally compared to known amino acid sequences in a 
database to identify likely candidates for the protein’s identity. Due to the protein’s size, 
Edmund degradation (identification of individual amino acids sequentially via 
biochemical analysis) is unlikely to be successful.  Unlike RT-PCR analysis, this method 
would identify post-translational alterations to the protein isoforms identified. Enzymatic 
activity with NR1 at the NMJ, miRNA interference or protein modification studies are all 
potential avenues for further research, dependent upon the outcome of the NR1 
sequencing studies. Correlation of any of these with skeletal muscle pathology offers the 
possibility of novel therapeutics and treatments.  
Physiological Role of Glutamate Receptors in Skeletal Muscle 
 A third goal of these studies was to determine functionality of NMDA receptors 
in skeletal muscle. Two methods were used to test functionality. First, we measured the 
effects of blocking the entire glutamatergic system in skeletal muscle and blocking 
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AMPA and NMDA receptors at this system. Using electrophysiology we observed that 
shutting down the glutamate system increases mEPP frequency and quantal content. In 
other words, there is an increase in vesicle release between axonal firing, suggesting 
instability in the neuronal firing mechanisms. Presumably, the next step would be to 
repeat the experiment in mdx mice, to determine whether this system functions differently 
in a disease model. In this experiment, we would first establish a baseline of the 
difference in mEPP frequency and quantal content between the untreated control mdx 
myocytes. We would then observe changes in mdx myocytes after treatment with 
glutamate agonists and antagonists.  
 Our second experiment was to excise expression of NR1 exclusively in skeletal 
muscle to disrupt NMDA receptor function. However, our hypothesis for that experiment 
was unable to be tested, as confocal microscopy revealed that our Cre-loxP system was 
not functioning as expected. In addition to the alternatives listed in Chapter IV, another 
potential idea would be to deliver adeno-associated virus (AAV) expressing Cre 
recombinase to skeletal muscle. This technique might allow for Cre to be expressed at 
high enough levels to excise floxed NR1 from synaptic nuclei. If, via a Cre induced 
mechanism or other means, we were able to ablate or disrupt receptors exclusively from 
skeletal muscle, the next step could be to generate a rescue model for any phenotypes 
observed due to NR1 cKO.  
 The purpose of excising the NR1 gene was to eliminate the NR1 protein. We have 
not yet correlated protein expression levels with disease; as stated above, a great barrier 
to determining protein expression levels has been finding a functional antibody for NR1. 
However, we might be able to decrease protein expression levels by using RNA 
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interference (RNAi) to down-regulate expression of NR1. In C57 BL/10 mice, knocking 
down the expression of the NR1 gene via micro-RNA (miRNA) or small interfering RNA 
(siRNA) could lead to demonstration of synaptic cells’ dependency on these receptors for 
normal function. That is to say, we might induce a phenotypical change in normal mice 
by impeding transcription or translation of the NR1 subunit. The caveat to this, 
unfortunately, is that without a working NR1 antibody, quantifying protein levels for 
confirmation of the system is still troublesome. 
 Glutamate toxicity, the “over-loading” of a synapse due to excess glutamate 
neurotransmitter, is another possibility which might be investigated in skeletal muscle. 
As the neuron is overwhelmed with glutamate, it becomes less sensitive to action 
potentials and eventually dies. Huntington’s disease, amyotrophic lateral sclerosis and 
several other neurodegenerative disorders display glutamate toxicity as a contributing to 
or resulting from pathogenesis [9]. An investigation into the localization of glutamate 
neurotransmitter in skeletal muscle recently showed severe disruption of glutamate in 
skeletal muscle. Localization exclusive to the NMJ in normal mice is rendered to 
uncontained, ubiquitous extracellular localization in severe models of mouse muscular 
dystrophy [Rafael-Fortney laboratory, unpublished]. Though the possibility exists that 
pathology causes this disruption as a phenotype, our physiology data of NMDA receptors 
in skeletal muscle suggest that the gluatamatergic system plays a role in normal NMJ 
functionality.  
 It would be worthwhile to quantify glutamate levels in skeletal muscle for 
comparison between normal and diseased state. Using 1H- and 13C-labeling and nuclear 
magnetic resonance (NMR), researchers have quantified glutamate levels in brain and 
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using heart respectively [58, 74]. Additionally, chromatography techniques (gas, HPLC) 
or enzymatic assays might be potential venues to determine glutamate levels. 
Limitations 
 There are two major limitations two the findings presented in this thesis. First, 
antibody specificity is still inconclusive. We tested numerous commercially-available 
NR1 antibodies in western blots and immunofluorescence, but the results were often 
inconclusive and somewhat contradicting. However, we propose that this is due to 
alternative splicing of the NR1 gene in skeletal muscle that is not consistently detected by 
antibodies we tested. The greatest challenge remains in finding (or perhaps designing) an 
antibody which can clearly and consistently detect the NR1 isoforms that we believe it 
exist at the NMJ. 
 Second, as mentioned in Chapter III, our physiology experiments were not 
statistically significant after a paired two-tailed t-test, due primarily to sample size. 
However, a definite trend of both increased mEPP frequency and quantal content could 
be observed after blocking the entire glutamate system. Given the dramatic difference 
seen between samples in the physiology traces, coupled with p values of nearly <0.05, we 
believe that increasing the sample size of semitendonosus muscles examined will show a 
significant difference between control and treated samples. For all mouse studies not 
involved with electrophysiology, generally >5 mice were tested in each experiment.  
Conclusion 
 Taken together, the data presented in this thesis provide credible evidence that the 
NR1 subunit is present and functional at the NMJ in murine skeletal muscle. The 
presence of NR1 has been demonstrated via immunofluorescence and western blotting, 
   
 67  
its expression determined via RT-PCR, and its functionality tested physiologically via 
single-cell electrophysiology studies with glutamate receptor agonists and antagonists. 
The presence of both NMDA receptors and AMPA receptors [38] is important in that it 
challenges a long-held dogma that the NMJ functions as a “simple cholinergic synapse.” 
An alternative glutamatergic system opens the door for novel therapeutics and treatments 
which might correlate with disease state of the NMJ. Insight into the workings of the 
NMJ can be revealed upon further investigation of this novel glutamatergic system.  
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Appendix A 
Key: Grin1/NR1 — Known sequence of NR1; 4_1_No_He—isolated sequence from skeletal muscle. 
 
Grin1/NR1   ACCCATGTCA TCCCAAATGA CAGGAAGATC ATCTGGCCAG GAGGAGAGAC AGAGAAGCCT 
            TGGGTACAGT AGGGTTTACT GTCCTTCTAG TAGACCGGTC CTCCTCTCTG TCTCTTCGGA 
            __________a__________a__________a__________a__________a__________> 
 
1. 4_1_No_He                                    10         20         30 
[  564 ]                               ANATN GCNAGANCNN AAAGACCCCN TTAAAAG-GG> 
                                       | ||      |  |    | ||        | |||    
Grin1/NR1                              AGATC ATCTGGCCAG GAGGAGAGAC AGAGAAGCCT 
 
 
                                                   1300                       
Grin1/NR1   CGAGGATACC AGATGTCCAC CAGACTAAAG ATAGTGACAA TCCACCAAGA ACCCTTCGTG 
            GCTCCTATGG TCTACAGGTG GTCTGATTTC TATCACTGTT AGGTGGTTCT TGGGAAGCAC 
            __________a__________a__________a__________a__________a__________> 
 
1. 4_1_No_He    40          50         60            70         80         90 
[  564 ]    CAAAAAAAGC ACCT-TCAGC NNGNCNNAGG A-A-TG-GGC TTCTNCANCN TTTTNGGGNT> 
            | |  | | | |  | ||  |   | |  | | | | ||     | |  ||           |   
Grin1/NR1   CGAGGATACC AGATGTCCAC CAGACTAAAG ATAGTGACAA TCCACCAAGA ACCCTTCGTG 
 
 
Grin1/NR1   TATGTCAAGC CCACAATGAG TGATGGCACA TGCAAAGAGG AGTTCACAGT CAATGGTGAC 
            ATACAGTTCG GGTGTTACTC ACTACCGTGT ACGTTTCTCC TCAAGTGTCA GTTACCACTG 
            __________a__________a__________a__________a__________a__________> 
 
1. 4_1_No_He       100        110           120         130        140 
[  564 ]    CNTGGTNTGN NTTTTTTGAN T--TGGTGTN TTTTTTTTGG -GCTCTGNAT CTNT-TTANT> 
              ||    |        |||  |  |||     |       ||  | ||    | |  |  |    
Grin1/NR1   TATGTCAAGC CCACAATGAG TGATGGCACA TGCAAAGAGG AGTTCACAGT CAATGGTGAC 
 
 
                             1400                                             
Grin1/NR1   CCTGTCAAGA AGGTGATCTG TACGGGGCCT AATGACACAT CCCCAGGAAG CCCACGTCAC 
            GGACAGTTCT TCCACTAGAC ATGCCCCGGA TTACTGTGTA GGGGTCCTTC GGGTGCAGTG 
            __________a__________a__________a__________a__________a__________> 
 
1. 4_1_No_He 150         160        170         180        190        200 
[  564 ]    TATNAC-TTA TATTGATTTN TNNNNNTTGG TAT-ACTCAN CATNTCNAAN GTGGANTAAT> 
              |  |   |    |||| |  |           || || ||  |      ||        | |  
Grin1/NR1   CCTGTCAAGA AGGTGATCTG TACGGGGCCT AATGACACAT CCCCAGGAAG CCCACGTCAC 
 
 
 
 
                                                                         1500 
Grin1/NR1   ACAGTGCCCC AGTGCTGTTA TGGCTTCTGC GTTGACCTGC TCATCAAGCT GGCACGGACC 
            TGTCACGGGG TCACGACAAT ACCGAAGACG CAACTGGACG AGTAGTTCGA CCGTGCCTGG 
            __________a__________a__________a__________a__________a__________> 
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            C 
            | 
1. 4_1_No_He| 210         220        230         240          250        260 
[  564 ]    ACGGTCACGC AGT-CTNAGC NTAAGTACG- GCNGANCT-C AC-NCNAGAA CGTCTNNCTC> 
            || ||  | | ||| ||          |  |  |  || || |  |  | ||    |       | 
Grin1/NR1   ACAGTGCCCC AGTGCTGTTA TGGCTTCTGC GTTGACCTGC TCATCAAGCT GGCACGGACC 
 
 
Grin1/NR1   ATGAATTTTA CCTACGAGGT GCACCTTGTG GCAGATGGCA AGTTTGGCAC ACAGGAGCGG 
            TACTTAAAAT GGATGCTCCA CGTGGAACAC CGTCTACCGT TCAAACCGTG TGTCCTCGCC 
            __________a__________a__________a__________a__________a__________> 
 
1. 4_1_No_He      270        280        290        300         310        320 
[  564 ]    ATGGCCGACA AGNNGAAGAA CGGCATCNAG GCGAACTNCC AGATCCGC-C ACAANATCGA> 
            |||      |       ||      | |   | ||  |   |  || |  || | |||  | ||  
Grin1/NR1   ATGAATTTTA CCTACGAGGT GCACCTTGTG GCAGATGGCA AGTTTGGCAC ACAGGAGCGG 
 
 
                                                   1600                       
Grin1/NR1   GTAAACAACA GCAACAAAAA GGAGTGGAAC GGAATGATGG GAGAGCTGCT CAGTGGTCAA 
            CATTTGTTGT CGTTGTTTTT CCTCACCTTG CCTTACTACC CTCTCGACGA GTCACCAGTT 
            __________a__________a__________a__________a__________a__________> 
 
1. 4_1_No_He          330          340        350         360        370 
[  564 ]    G--GACGGGG GC--GTGCAG CTCGCCCACC ACTACCAGCA GA-ACACCCC CANCGGCGAC> 
            |   ||     ||      |     |   | |    |  |    || |    |  ||  ||  |  
Grin1/NR1   GTAAACAACA GCAACAAAAA GGAGTGGAAC GGAATGATGG GAGAGCTGCT CAGTGGTCAA 
 
 
Grin1/NR1   GCAGACATGA TCGTGGCTCC ACTGACCATT AACAATGAGC GTGCGCAGTA CATAGAGTTC 
            CGTCTGTACT AGCACCGAGG TGACTGGTAA TTGTTACTCG CACGCGTCAT GTATCTCAAG 
            __________a__________a__________a__________a__________a__________> 
 
1. 4_1_No_He  380         390         400          410           420 
[  564 ]    GGCNCCGTGC T-GCTGC-CC GANNACCACT -AC-CTGAGC --ACCCAGNG CA-A-ACTTN> 
            |    | ||  | |  || ||     |||| |  ||  |||||    | |||   || | | ||  
Grin1/NR1   GCAGACATGA TCGTGGCTCC ACTGACCATT AACAATGAGC GTGCGCAGTA CATAGAGTTC 
 
 
 
 
 
                             1700                                             
Grin1/NR1   TCCAAGCCCT TCAAGTACCA GGGCCTGACC ATTCTGGTCA AGAAGGAGAT CCCTCGGAGC 
            AGGTTCGGGA AGTTCATGGT CCCGGACTGG TAAGACCAGT TCTTCCTCTA GGGAGCCTCG 
            __________a__________a__________a__________a__________a__________> 
 
                AC                                                 G 
                 |                                                 | 
1. 4_1_No_He430  |   440        450        460        470        480      490 
[  564 ]    CGAAAGCCCA ACGAGAAGCG NGATCACNTG GNCCTGCTGG AGTTCGNGAC CCCGCCGGGA> 
               ||||||   | || | |   |  |         ||| |   ||   | ||  ||| | | |  
Grin1/NR1   TCCAAGCCCT TCAAGTACCA GGGCCTGACC ATTCTGGTCA AGAAGGAGAT CCCTCGGAGC 
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                                                                          1800 
Grin1/NR1   ACACTGGACT CATTCATGCA GCCCTTTCAG AGCACACTGT GGCTGCTGGT GGGGCTGTCA 
            TGTGACCTGA GTAAGTACGT CGGGAAAGTC TCGTGTGACA CCGACGACCA CCCCGACAGT 
            __________a__________a__________a__________a__________a__________> 
 
                                              GG             A GAGCA 
                                               |             |   | 
1. 4_1_No_He       500        510        520   |  530       540  |550 
[  564 ]    TCACTCTCGG CATGGACGTA GCTGGACAAG GGCTNCCGGA GGGAGCTGGN NGGGCGAGGA> 
             ||||      |||  | | | ||      ||  ||   | |  ||  |||||   ||||    | 
Grin1/NR1   ACACTGGACT CATTCATGCA GCCCTTTCAG AGCACACTGT GGCTGCTGGT GGGGCTGTCA 
 
Grin1/NR1   GTTCATGTGG TGGCCGTGAT GCTGTACCTG CTGGACCGCT TCAGTCCCTT TGGCCGATTT 
            CAAGTACACC ACCGGCACTA CGACATGGAC GACCTGGCGA AGTCAGGGAA ACCGGCTAAA 
            __________a__________a__________a__________a__________a__________> 
 
           CTG  C 
            |   | 
1. 4_1_No_He|   |570        580        590        600         610        620 
[  564 ]    GTTCACGGGG TGGTGCCCAT CCTGGNCGAG CTGGACGGCG AC-GTAGACG GCCACAANTT> 
            ||||| | || |||     ||  |||  |  | |||||| ||   | ||          | | || 
Grin1/NR1   GTTCATGTGG TGGCCGTGAT GCTGTACCTG CTGGACCGCT TCAGTCCCTT TGGCCGATTT 
 
                                                   1900                       
Grin1/NR1   AAGGTGAACA GCGAGGAGGA GGAGGAGGAT GCACTGACCC TGTCCTCTGC CATGTGGTTT 
            TTCCACTTGT CGCTCCTCCT CCTCCTCCTA CGTGACTGGG ACAGGAGACG GTACACCAAA 
            __________a__________a__________a__________a__________a__________> 
  
             C 
              | 
1. 4_1_No_He  |  630        640        650          660          670 
[  564 ]    CAGGTGTCCG GCGAGGGTGA GGGCGATGCC NC-CT-ACGG CNAGCT-GAC CCTGAAGTTC> 
             |||||  |  ||||||  || ||  || |    | || ||       ||   | | ||  |||  
Grin1/NR1   AAGGTGAACA GCGAGGAGGA GGAGGAGGAT GCACTGACCC TGTCCTCTGC CATGTGGTTT 
 
Grin1/NR1   TCCTGGGGCG TCCTGCTCAA CTCTGGCATT GGGGAAGGTG CCCCCCGGAG TTTCTCTGCT 
            AGGACCCCGC AGGACGAGTT GAGACCGTAA CCCCTTCCAC GGGGGGCCTC AAAGAGACGA 
            __________a__________a__________a__________a__________a__________> 
 
                                                                 A 
                                                                 | 
1. 4_1_No_680         690           700        710        720    |  730 
[  564 ]    ATCT-GCACC ACC-G-GCAA -GCTGCCCCG NGCCCTGNCC CNCCCNCGAG CCACNCTG-A> 
              || |  |   || |  |||   ||| |     |    |    | |||  |||    | |||   
Grin1/NR1   TCCTGGGGCG TCCTGCTCAA CTCTGGCATT GGGGAAGGTG CCCCCCGGAG TTTCTCTGCT 
 
                             2000                                             
Grin1/NR1   CGTATCCTAG GCATGGTGTG GGCTGGTTTT GCCATGATCA TCGTGGCTTC CTACACTGCC 
            GCATAGGATC CGTACCACAC CCGACCAAAA CGGTACTAGT AGCACCGAAG GATGTGACGG 
            __________a__________a__________a__________a__________a__________> 
 
                                                                       T 
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                                                                       | 
1. 4_1_No_He  740        750        760        770         780         | 
[  564 ]    CCTACGGCGT GCANCGCTNC AACCGCTACC CCGACCA-NA TGAAGGNGCN CAACNCTNCN> 
            | ||       |||  |       | | |     | |  |  | |   ||     | || || |  
Grin1/NR1   CGTATCCTAG GCATGGTGTG GGCTGGTTTT GCCATGATCA TCGTGGCTTC CTACACTGCC 
 
                                                                         2100 
Grin1/NR1   AACCTGGCAG CCTTCCTGGT GCTGGATAGG CCTGAGGAGC GCATCACAGG CATCAATGAC 
            TTGGACCGTC GGAAGGACCA CGACCTATCC GGACTCCTCG CGTAGTGTCC GTAGTTACTG 
            __________a__________a__________a__________a__________a__________> 
 
            G                                                        N 
            |                                                        | 
1. 4_1_No_He|800         810         820          830        840     | 850 
[  564 ]    AGTCCGCCAN GC-CCCGAGG GC-CTACA-T CCAG-GGAAC GCACCATCTT CGTCAAGGAC> 
            |  | | ||   |  ||  |  ||   | |   || | ||| | ||| ||     | |||| ||| 
Grin1/NR1   AACCTGGCAG CCTTCCTGGT GCTGGATAGG CCTGAGGAGC GCATCACAGG CATCAATGAC 
 
Grin1/NR1   CCCAGGCTCA GAAACCCCTC AGACAAGTTC ATCTATGCAA CTGTAAAACA GAGCTCTGTG 
            GGGTCCGAGT CTTTGGGGAG TCTGTTCAAG TAGATACGTT GACATTTTGT CTCGAGACAC 
            __________a__________a__________a__________a__________a__________> 
 
                 AA 
                  | 
1. 4_1_No_He    860      870         880        890          900         910 
[  564 ]    GACGGGCCTA CAAGACCCGC -GCCGAGGNT GAAGNTTCGA --GGGCGACA -CCCTGGGT-> 
              | |||  |  ||  ||| |  | | ||         | | |   |    |||    ||  || 
Grin1/NR1   CCCAGGCTCA GAAACCCCTC AGACAAGTTC ATCTATGCAA CTGTAAAACA GAGCTCTGTG 
 
                                                   2200                       
Grin1/NR1   GATATCTACT TCCGGAGGCA GGTGGAGTTG AGCACCATGT ACCGGCACAT GGAGAAGCAC 
            CTATAGATGA AGGCCTCCGT CCACCTCAAC TCGTGGTACA TGGCCGTGTA CCTCTTCGTG 
            __________a__________a__________a__________a__________a__________> 
 
                                               T       GGA    N CC 
                                               |        |     |  | 
1. 4_1_No_He         920        930         940|      950     |  |   970 
[  564 ]    GA-ACCGCAT CCNAGCTGAA GG-GGNATCG ACCTCAAGGG ACGGNNACAT CGGGGGGCAC> 
            || | |   |  |  |  | | || ||  | | | | | | |  || |  ||||  | |  |||| 
Grin1/NR1   GATATCTACT TCCGGAGGCA GGTGGAGTTG AGCACCATGT ACCGGCACAT GGAGAAGCAC 
 
 
Grin1/NR1   AATTATGAGA GTGCAGCTGA GGCCATCCAG GCTGTGCGGG ACAACAAGCT CCATGCCTTC 
            TTAATACTCT CACGTCGACT CCGGTAGGTC CGACACGCCC TGTTGTTCGA GGTACGGAAG 
            __________a__________a__________a__________a__________a__________> 
 
                        A    A 
                        |    | 
1. 4_1_No_He  980       990  |   1000          1010         1020       1030 
[  564 ]    AAGNCTGGGA NTNCAACCGC NGGGA-CCA- ACCG-GACTG A-AA-AAGCG AATCGCNGAA> 
            ||   || ||  | || | |   |  | |||   | | |   | | || ||||      ||     
Grin1/NR1   AATTATGAGA GTGCAGCTGA GGCCATCCAG GCTGTGCGGG ACAACAAGCT CCATGCCTTC 
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                             2300                                             
Grin1/NR1   ATCTGGGACT CAGCTGTGCT GGAGTTTGAG GCTTCACAGA AGTGCGATCT GGTGACCACG 
            TAGACCCTGA GTCGACACGA CCTCAAACTC CGAAGTGTCT TCACGCTAGA CCACTGGTGC 
            __________a__________a__________a__________a__________a__________> 
 
               A 
               | 
1. 4_1_No_He   1040       1050       1060       1070          1080       1090 
[  564 ]    ATTTAAGAGG CNTNTCNCCC CTANTTGGAC CAGGGACCG- -G-GGGANNG GGANAAAAAN> 
            || |  ||   |   |   |    | || ||       || |   | | ||    ||  |  |   
Grin1/NR1   ATCTGGGACT CAGCTGTGCT GGAGTTTGAG GCTTCACAGA AGTGCGATCT GGTGACCACG 
 
                                                                         2400 
Grin1/NR1   GGTGAGCTGT TCTTCCGCTC CGGCTTTGGC ATCGGCATGC GCAAGGACAG CCCCTGGAAG 
            CCACTCGACA AGAAGGCGAG GCCGAAACCG TAGCCGTACG CGTTCCTGTC GGGGACCTTC 
            __________a__________a__________a__________a__________a__________> 
 
1. 4_1_No_He      1100       1110           1120       1130 
[  564 ]    AACCANAGGN NCTTGGGGAN CGGNNANGG- --NGGTCTCC NNGGGGNCA> 
                |   |   |||  |    |||    ||     ||  | |     || || 
Grin1/NR1   GGTGAGCTGT TCTTCCGCTC CGGCTTTGGC ATCGGCATGC GCAAGGACA 
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